The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia
出版年份 2023 全文链接
标题
The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia
作者
关键词
-
出版物
Journal of Clinical Lipidology
Volume 17, Issue 3, Pages 392-400
出版商
Elsevier BV
发表日期
2023-04-30
DOI
10.1016/j.jacl.2023.04.010
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
- (2023) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys
- (2022) Dario Lehoux et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
- (2022) Lei Bi et al. Frontiers in Cardiovascular Medicine
- Clinical Pharmacology of RNA Interference–Based Therapeutics: A Summary Based on Food and Drug Administration–Approved Small Interfering RNAs
- (2022) Xing Jing et al. DRUG METABOLISM AND DISPOSITION
- The growth of siRNA-based therapeutics: updated clinical studies
- (2021) M. May Zhang et al. BIOCHEMICAL PHARMACOLOGY
- Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1
- (2021) Yaacov Frishberg et al. Clinical Journal of the American Society of Nephrology
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
- (2020) Bahru A. Habtemariam et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
- (2020) Manisha Balwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of China’s Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease
- (2020) Miao Wang et al. Global Heart
- Genetic Inhibition of PCSK9 and Liver Function
- (2020) Antoine Rimbert et al. JAMA Cardiology
- Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
- (2019) Eliane Sardh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Trends in Non-HDL-Cholesterol and LDL-Cholesterol Levels in Adults with Atherosclerotic Cardiovascular Disease
- (2019) Gloria Lena Vega et al. Journal of Clinical Lipidology
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
- (2019) Charles A. German et al. BIODRUGS
- Inclisiran—New hope in the management of lipid disorders?
- (2019) Krzysztof Dyrbuś et al. Journal of Clinical Lipidology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults
- (2018) Mei Zhang et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
- (2018) Kyle J Foreman et al. LANCET
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- No evidence to support high-intensity statin in Chinese patients with coronary heart disease
- (2016) Wen Dai et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease
- (2015) Simon Barquera et al. ARCHIVES OF MEDICAL RESEARCH
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now